CN104351612A - 一种海参灵芝葡聚糖硒制剂及其制备方法 - Google Patents
一种海参灵芝葡聚糖硒制剂及其制备方法 Download PDFInfo
- Publication number
- CN104351612A CN104351612A CN201410671584.5A CN201410671584A CN104351612A CN 104351612 A CN104351612 A CN 104351612A CN 201410671584 A CN201410671584 A CN 201410671584A CN 104351612 A CN104351612 A CN 104351612A
- Authority
- CN
- China
- Prior art keywords
- sea cucumber
- glucan
- preparation
- parts
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000251511 Holothuroidea Species 0.000 title claims abstract description 77
- 229920001503 Glucan Polymers 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 45
- 241000222336 Ganoderma Species 0.000 title claims abstract description 33
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 title claims abstract description 23
- 239000011669 selenium Substances 0.000 title claims abstract description 23
- 229910052711 selenium Inorganic materials 0.000 title claims abstract description 23
- 239000000843 powder Substances 0.000 claims abstract description 47
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 29
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 241000206575 Chondrus crispus Species 0.000 claims description 25
- 150000003346 selenoethers Chemical class 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 10
- 235000013305 food Nutrition 0.000 claims description 7
- 210000000936 intestine Anatomy 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 238000004806 packaging method and process Methods 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 241000965254 Apostichopus japonicus Species 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 6
- 210000001835 viscera Anatomy 0.000 claims description 6
- 238000010792 warming Methods 0.000 claims description 6
- 235000020985 whole grains Nutrition 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 238000013019 agitation Methods 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims description 3
- 238000000498 ball milling Methods 0.000 claims description 3
- 238000010009 beating Methods 0.000 claims description 3
- 239000007910 chewable tablet Substances 0.000 claims description 3
- 229940068682 chewable tablet Drugs 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 230000002255 enzymatic effect Effects 0.000 claims description 3
- 210000004700 fetal blood Anatomy 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000019634 flavors Nutrition 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000007902 hard capsule Substances 0.000 claims description 3
- 239000007887 hard shell capsule Substances 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 238000005507 spraying Methods 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 238000009461 vacuum packaging Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 239000000080 wetting agent Substances 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 abstract description 16
- 239000008280 blood Substances 0.000 abstract description 16
- 230000036039 immunity Effects 0.000 abstract description 16
- 150000002632 lipids Chemical class 0.000 abstract description 10
- 230000005855 radiation Effects 0.000 abstract description 10
- 230000036541 health Effects 0.000 abstract description 9
- 230000008901 benefit Effects 0.000 abstract description 3
- 229920001525 carrageenan Polymers 0.000 abstract 2
- 229940113118 carrageenan Drugs 0.000 abstract 2
- 235000010418 carrageenan Nutrition 0.000 abstract 2
- 239000000679 carrageenan Substances 0.000 abstract 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 abstract 2
- 239000002131 composite material Substances 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 6
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 206010022437 insomnia Diseases 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 241000700605 Viruses Species 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 208000033065 inborn errors of immunity Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000005670 electromagnetic radiation Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000005760 tumorsuppression Effects 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 244000139693 Arctostaphylos uva ursi Species 0.000 description 1
- 235000012871 Arctostaphylos uva ursi Nutrition 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010006179 Breast atrophy Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000035126 Facies Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 229930188089 Holothurin Natural products 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- -1 Tumor suppression Substances 0.000 description 1
- 206010046792 Uterine hypotonus Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 235000005770 birds nest Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000005961 cardioprotection Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- MAWWITJOQDJRJF-ADBICINLSA-M holothurin Chemical compound [Na+].O[C@@H]1[C@@H](OC)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O[C@H]3[C@@H](OC[C@H]([C@@H]3O)OS([O-])(=O)=O)O[C@@H]3C([C@H]4[C@](C=5[C@H]([C@@]6(CC[C@]7(O)[C@](C)([C@H]8OC(C)(C)CC8)OC(=O)[C@@]76[C@@H](O)C=5)C)CC4)(C)CC3)(C)C)O[C@@H]2C)O)O[C@H](C)[C@H]1O MAWWITJOQDJRJF-ADBICINLSA-M 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000000191 radiation effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000002476 tumorcidal effect Effects 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 235000005765 wild carrot Nutrition 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/256—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from seaweeds, e.g. alginates, agar or carrageenan
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明涉及保健品技术领域，具体地说是一种集海参、灵芝、酵母B-葡聚糖、硒元素一体的海参灵芝葡聚糖硒制剂及其制备方法，其特征在于该制剂由海参、灵芝孢子粉、酵母B-葡聚糖和硒化卡拉胶组成，其中海参、灵芝孢子粉、酵母B-葡聚糖和硒化卡拉胶各组分的重量配比为：海参粉34~40份，灵芝孢子粉30~33份，酵母B-葡聚糖29~32份，硒化卡拉胶1~2份，将各种原料制粉混合制粒，本发明由于采用上述组合物制剂，具有高效的提高免疫力、防辐射、降血脂能力等优点。
Description
技术领域
本发明涉及保健品技术领域，具体地说是一种集海参、灵芝孢子粉、酵母B-葡聚糖、硒元素一体的海参灵芝葡聚糖硒制剂及其制备方法。
背景技术
随着社会的发展，人们生活水平的提高，人们对自身健康的重视程度也越来越大，但是由于工作节奏加快、工作压力的增大，人们的免疫力普遍低下，免疫力是人体自身的防御机制，是人体识别和消灭外来侵入的任何异物（病毒、细菌等），处理衰老、损伤、死亡、变性的自身细胞以及识别和处理体内突变细胞和病毒感染细胞的能力，免疫力低下的身体易于被感染或患癌症，免疫力超常也会产生对身体有害的结果，如引发过敏反应、自身免疫疾病等，各种原因使免疫***不能正常发挥保护作用，在此情况下，极易招致细菌、病毒、真菌等感染，因此免疫力低下最直接的表现就是容易生病。
同时，由于当今信息网络的快速发展，辐射污染已经影响到我们的生活，辐射污染会影响人体的循环***、免疫、生殖和代谢功能，严重的还会诱发癌症、并会加速人体的癌细胞增殖，影响人们的生殖***主要表现为男子***质量降低，孕妇发生自然流产和胎儿畸形等，影响人们的心血管***表现为心悸、失眠，部分女性***、心动过缓、心搏血量减少、窦性心率不齐、白细胞减少、免疫功能下降等，对人们的视觉***有不良影响由于眼睛属于人体对电磁辐射的敏感器官，过高的电磁辐射污染还会对视觉***造成影响，主要表现为视力下降，引起白内障等。
发明内容
本发明的目的是解决上述现有技术的不足，提供一种集海参、灵芝孢子粉、酵母B-葡聚糖、硒元素一体的提高免疫力、防辐射和降血脂的海参灵芝葡聚糖硒制剂及其制备方法。
本发明解决其技术问题所采用的技术方案是：
一种海参灵芝葡聚糖硒制剂，其特征在于该制剂由海参、灵芝孢子粉、酵母B-葡聚糖和硒化卡拉胶组成，其中海参、灵芝孢子粉、酵母B-葡聚糖和硒化卡拉胶各组分的重量配比为：海参粉34~40份，灵芝孢子粉30~33份，酵母B-葡聚糖29~32份，硒化卡拉胶1~2份。
一种海参灵芝葡聚糖硒制剂的制作方法，其特征在于制作步骤如下：
(1)：首相将新鲜海参洗净、剪开、出去内脏，海参体壁内含有海参自溶酶的液体留作备用，将海参内脏中的海参肠和海参花中的杂质除净，海参肠和海参花一并备用，然后将备用的海参原料粉碎后球磨打浆，加入酶解罐中，再加入海参原料重的5~10倍的水，加入海参体壁内含有海参自溶酶的液体和风味酶适量，混合均匀，打开蒸汽开关，逐渐升温至45~46℃，持续搅拌的条件下维持恒温3.5~4小时，待整个液体基本澄清升温至100℃，5~10分钟后，降温过滤，将所得澄清滤液调整浓度为2~10%，然后用洁净的喷干塔进行喷雾干燥，所得喷干粉检验合格后，塑料袋真空包装，低温保存，备用；
(2)：将购买的破壁灵芝孢子粉检验合格备用，将酵母B-葡聚糖按新资源食品标准检验合格备用，将硒化卡拉胶检验合格备用；
(3)：将合格的海参粉、破壁灵芝孢子粉、酵母B-葡聚糖和硒化卡拉胶按照重量比海参粉34~40份，灵芝孢子粉30~33份，酵母B-葡聚糖29~32份，硒化卡拉胶1~2份取用，精密称重，然后用三维混合机混合均匀；
(4)：将步骤(3)所得的混合物用低醇做湿润剂，按照常规方法制粒，然后进行干燥，整粒，混合均匀。
本发明所述的一种海参灵芝葡聚糖硒制剂的制作方法，其特征在于整粒后按照生产工艺流程用颗粒分装机制成颗粒制剂，检验合格包装。
本发明所述的一种海参灵芝葡聚糖硒制剂的制作方法，其特征在于混合物按照硬胶囊生产工艺流程制成硬胶囊制剂，检验合格包装。
本发明所述的一种海参灵芝葡聚糖硒制剂的制作方法，其特征在于混合物压片制成咀嚼片剂，检验合格包装。
本发明成分分析
海参，是海味“八珍”之一，与燕窝、鲍鱼、鱼翅齐名，性微寒，味甘、咸，归肺、肾、大肠经，有补肾益精、养血润燥等功效，医学上常用于主治精血亏损；虚弱劳怯；阳痿；梦遗；肠燥便秘；肺虚咳嗽、咯血，肠风便血，外伤出血等，素有“百病之克星”、“长寿之神”、“百补之首”、“补血之神”等美誉，是高蛋白滋补食品，海参的主要有蛋白质、多肽、海参素、粘多糖、脂类等多种营养成分，具有广谱的抗肿瘤作用，抑制癌细胞的生长于转移，对恶性肿瘤的生长、转移具有显著抑制作用，有抗炎、成骨作用，对肝炎患者、结核病、糖尿病、心血管疾病有显著的治疗作用，药用保健价值极高。
灵芝孢子粉，是灵芝在发育后期产生释放来的种子，是灵芝的精华，其药性为甘，平，归心、肝、脾、肺、肾五经，它能显著提高人体免疫能力，也能迅速激发神经***产生应急调节反应，疏导及恢复营养组织通道，修复损伤组织和促进细胞再生，对抑制肿瘤及肿瘤组织端粒酶活性具有显著疗效，且高破壁率的灵芝孢子粉能使灵芝孢子的有效成分最大程度地被人体利用吸收，破壁后人体对灵芝孢子粉的吸收率可提高 45 倍之多，破壁孢子粉比不破壁孢子粉具有更强的体外毒杀癌细胞的活性，灵芝孢子粉是最佳的免疫功能调节剂和激活剂，它可显著提高机体的免疫功能，增强患者自身的防癌、抗癌能力。灵芝可以通过促进白细胞介素-2的等内源性抗癌物质的生成，通过促进单核巨噬细胞的吞噬功能、通过提升人体的造血能力尤其是白细胞的指标水平，以及通过其中某些有效成分对癌细胞的抑制作用，且灵芝用于治疗慢性中毒、各类慢性肝炎、肝硬化、肝功能障碍，同时具有抗老化，抗神经衰弱，肌肤美白等功效。
酵母B-葡聚糖，又称右旋糖酐，为一种多糖，存在于某些微生物在生长过程中分泌的粘液中，被誉为“超级灵芝”、“定向清毒，免疫先锋”、“病毒细胞的追捕者”以及“肿瘤患者最后的希望”等，具有增强免疫、抗辐射、调节血脂的作用，主要药理特性有增强人体免疫***，快速调节免疫，清除的自由基，激活巨噬细胞、噬中性细胞等清除由辐射造成细胞分解碎片，能够使巨噬细胞辨别和破坏变异细胞，协助受损组织如淋巴组织细胞加速恢复产生细胞素（IL-1），促使包括抗生素，抗真菌，抗寄生药在内的其他药物更好地发挥效用，减低血液中的低密度脂肪，提高高密度脂肪，减少高血脂的发生，抑制肿瘤，抗氧化、辐射作用，帮助身体组织结构再生和修复，促进伤口愈合，润肠通便、调节胃肠功能、降低胆固醇。
硒化卡拉胶，是人体必需的微量元素，人体内含硒化卡拉胶量最丰富的器官就是肝，可以减少有毒物质对肝脏的伤害并帮助肝脏解毒，拮抗和降低多种重金属的毒作用，可以保护肺、肝脏、心脏和眼睛等多个器官，具有抗氧化、提高免疫力、延缓衰老、增强生殖能力等功能，能增强分布在肝细胞液和线粒体中的谷胱甘肽过氧化物酶的活性，清除自由基及脂质过氧化物，加速肝功能的改善过到保护肝脏的目的，硒元素能有效的清除自由基，保护心脏，防治心脑血管病变。
本发明由于采用上述组合物制剂，具有高效的提高免疫力、防辐射、降血脂能力等优点。
具体实施方式
一种海参灵芝葡聚糖硒制剂，其特征在于该制剂由海参、灵芝孢子粉、酵母B-葡聚糖和硒化卡拉胶组成，其中海参、灵芝孢子粉、酵母B-葡聚糖和硒化卡拉胶各组分的重量配比为：海参粉34~40份，灵芝孢子粉30~33份，酵母B-葡聚糖29~32份，硒化卡拉胶1~2份，制作时，首相将新鲜海参洗净、剪开、出去内脏，海参体壁内含有海参自溶酶的液体留作备用，将海参内脏中的海参肠和海参花中的杂质除净，海参肠和海参花一并备用，然后将备用的海参原料粉碎后球磨打浆，加入酶解罐中，再加入海参原料重的5~10倍的水，加入海参体壁内含有海参自溶酶的液体和风味酶适量，混合均匀，打开蒸汽开关，逐渐升温至45~46℃，持续搅拌的条件下维持恒温3.5~4小时，待整个液体基本澄清升温至100℃，5~10分钟后，降温 过滤，将所得澄清滤液调整浓度为2~10%，然后用洁净的喷干塔进行喷雾干燥，所得喷干粉检验合格后，塑料袋真空包装，低温保存，备用，然后将购买的破壁灵芝孢子粉检验合格备用，将酵母B-葡聚糖按新资源食品标准检验合格备用，将硒化卡拉胶检验合格备用，将合格的海参粉、破壁灵芝孢子粉、酵母B-葡聚糖和硒化卡拉胶按照重量比海参粉38份，灵芝孢子粉32份，酵母B-葡聚糖30份，硒化卡拉胶1份取用，精密称重，然后用三维混合机混合均匀；将上述所得的混合物用低醇做湿润剂，按照常规方法制粒，然后进行干燥，整粒，混合均匀，整粒后按照生产工艺流程用颗粒分装机制成颗粒制剂，或按照硬胶囊生产工艺流程制成硬胶囊制剂，或压片制成咀嚼片剂，检验合格包装。
以下实验表明该发明的一种海参灵芝葡聚糖硒制剂，对增强免疫力、防辐射、降血脂有明显的功效。
1.增强免疫力
选取60只小鼠同龄且各种生化指标正常且相同的小鼠，雌雄各半，平均分为四组，每组15只，一组为对照组，三组为实验组，对照组正常喂食日常饲料，实验组分别喂养不同剂量的该发明养生制品，一组100mg/kg低量组，二组组为200mg/kg中量组，三组为600mg/kg高量组，其它喂养条件和环境相同，经一个月后，每组随机选取10 只小鼠，分别称取小鼠免疫器脾脏、胸腺、肝脏，称重，对照组4.865mg/g，一组低量组6.945 mg/g，二组中量组8.421mg/g，三组高量组7.853 mg/g，由此可见，对照组与一组、二组、三组差别很大，一组、二组、三组之间差别不大；
综上所述，本发明对人体免疫力有明显的提高，具有增强免疫力的功能。
2.防辐射
选取30只同龄且各种生化指标正常且相同的小鼠，雌雄各半，平均分为两组，每组15只，一组为对照组，另一组组为实验组，对照组正常喂食日常饲料，实验组分别喂养该发明养生制品，经过一个月后，对30只小鼠进行同等剂量的X光线照射，然后对小鼠进行指标检测，结果表明，对照组小白鼠脑细胞、DNA结构等均呈现被破坏的迹象，而且损坏程度比实验组小鼠差不多高一倍，因此，本发明对辐射有抵抗作用。
3.降血脂
选取30只同龄且各种生化指标正常且相同的小鼠，雌雄各半，平均分为二组，一组为对照组，二组为实验组，两组用同样的高脂肪饲料喂食7天，诱导建立高血脂小鼠模型，然后将一组正常饲料喂养，二组在正常饲料喂养的情况下喂养本发明制剂，经过30天后检测血脂含量，一组无明显降低，二组试验小鼠血脂明显降低，结果表明，该发明制剂对降血脂有很大功效。
实施例1
海参34份，灵芝孢子粉33份，酵母B-葡聚糖29份，硒化卡拉胶1份。
实施例2
海参40份，灵芝孢子粉33份，酵母B-葡聚糖32份，硒化卡拉胶2份。
实施例3
海参36份，灵芝孢子粉32份，酵母B-葡聚糖30份，硒化卡拉胶1份。
实施例4
海参35份，灵芝孢子粉31份，酵母B-葡聚糖31份，硒化卡拉胶2份。
实施例5
海参39份，灵芝孢子粉32份，酵母B-葡聚糖30份，硒化卡拉胶1份。
人群试食结果
1. 跟踪50例患者，此50例患者，免疫力低，天气稍有变化即感冒，平
均1-2 个月患感冒一次，每天睡前服用本发明养生制品，服用2 个月后，免疫力提高，能抵抗天气的变化，患感冒次数明显减少。
2.蔡某，山东人，由于工作压力增大，常常失眠多梦，免疫力下降，浑身无力，经服用本发明制剂后，面色明显红润，抵抗力提高，有活力。
3.胡某，山东人，女，情绪波动、失眠、记忆力减退、***、***减退、***萎缩、皮肤变得粗糙晦暗、弹性减退、毛孔粗大、皱纹加深，经服用本发明所述制品一个月后，睡眠质量好，睡眠深，记忆力增加、月经正常皮肤红润，有光泽，皮肤有弹性，皱纹减少。
4.李某，山东人，高血脂患者，经服用本发明所述的海参雪莲养生制品二个月后，检查，血粘度达到正常值。
5. 王某，男，25 岁，从事网络工作多年，免疫力低下，失眠，多梦，经服用本发明制剂，精力充沛，免疫力提高，感觉身体明显有力气。
由此可见，经服用本发明所述的海参灵芝葡聚糖硒制剂，对增强免疫力、防辐射和降血脂等有明显的功效。
Claims (5)
1.一种海参灵芝葡聚糖硒制剂，其特征在于该制剂由海参、灵芝孢子粉、酵母B-葡聚糖和硒化卡拉胶组成，其中海参、灵芝孢子粉、酵母B-葡聚糖和硒化卡拉胶各组分的重量配比为：海参粉34~40份，灵芝孢子粉30~33份，酵母B-葡聚糖29~32份，硒化卡拉胶1~2份。
2. 一种海参灵芝葡聚糖硒制剂的制作方法，其特征在于制作步骤如下：
(1)：首先将新鲜海参洗净、剪开、出去内脏，海参体壁内含有海参自溶酶的液体留作备用，将海参内脏中的海参肠和海参花中的杂质除净，海参肠和海参花一并备用，然后将备用的海参原料粉碎后球磨打浆，加入酶解罐中，再加入海参原料重的5~10倍的水，加入海参体壁内含有海参自溶酶的液体和风味酶适量，混合均匀，打开蒸汽开关，逐渐升温至45~46℃，持续搅拌的条件下维持恒温3.5~4小时，待整个液体基本澄清升温至100℃，5~10分钟后，降温过滤，将所得澄清滤液调整浓度为2~10%，然后用洁净的喷干塔进行喷雾干燥，所得喷干粉检验合格后，塑料袋真空包装，低温保存，备用；
(2)：将购买的破壁灵芝孢子粉检验合格备用，将酵母B-葡聚糖按新资源食品标准检验合格备用，将硒化卡拉胶检验合格备用；
(3)：将合格的海参粉、破壁灵芝孢子粉、酵母B-葡聚糖和硒化卡拉胶按照重量比海参粉34~40份，灵芝孢子粉30~33份，酵母B-葡聚糖29~32份，硒化卡拉胶1~2份取用，精密称重，然后用三维混合机混合均匀；
(4)：将步骤(3)所得的混合物用低醇做湿润剂，按照常规方法制粒，然后进行干燥，整粒，混合均匀。
3.根据权利要求2所述的一种海参灵芝葡聚糖硒制剂的制作方法，其特征在于整粒后按照生产工艺流程用颗粒分装机制成颗粒制剂。
4. 根据权利要求2所述的一种海参灵芝葡聚糖硒制剂的制作方法，其特征在于混合物按照硬胶囊生产工艺流程制成硬胶囊制剂。
5. 根据权利要求2所述的一种海参灵芝葡聚糖硒制剂的制作方法，其特征在于混合物压片制成咀嚼片剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410671584.5A CN104351612A (zh) | 2014-11-21 | 2014-11-21 | 一种海参灵芝葡聚糖硒制剂及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410671584.5A CN104351612A (zh) | 2014-11-21 | 2014-11-21 | 一种海参灵芝葡聚糖硒制剂及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104351612A true CN104351612A (zh) | 2015-02-18 |
Family
ID=52519003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410671584.5A Pending CN104351612A (zh) | 2014-11-21 | 2014-11-21 | 一种海参灵芝葡聚糖硒制剂及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104351612A (zh) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106213494A (zh) * | 2016-07-26 | 2016-12-14 | 柳州定店科技有限公司 | 一种虚弱体质调理的滋补药膳 |
| CN106690121A (zh) * | 2016-11-14 | 2017-05-24 | 威海力元海洋生物科技有限公司 | 一种海参沙棘虫草硒制剂及其制备工艺 |
| CN106723075A (zh) * | 2016-11-14 | 2017-05-31 | 威海力元海洋生物科技有限公司 | 一种双参沙棘g蛋白肉苁蓉锌硒制剂及其制备方法 |
| CN106723068A (zh) * | 2016-11-14 | 2017-05-31 | 威海力元海洋生物科技有限公司 | 一种海参番茄红素硒抗辐射胶囊配方及其制备工艺 |
| CN112790306A (zh) * | 2019-11-14 | 2021-05-14 | 舒培健康科学有限公司 | 一种用于补充气血的复合型小分子肽营养饮品及其制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526445A (zh) * | 2011-11-07 | 2012-07-04 | 宁波海逸生物科技有限公司 | 一种增强免疫力、缓解体力疲劳、抗肿瘤功能的保健药物配方 |
| CN102907558A (zh) * | 2012-11-16 | 2013-02-06 | 山东省海洋水产研究所 | 一种海参多肽的加工方法 |
| CN102987203A (zh) * | 2012-12-05 | 2013-03-27 | 无锡市天赐康生物科技有限公司 | 一种提高免疫力、降血脂的保健食品及其制备方法 |
-
2014
- 2014-11-21 CN CN201410671584.5A patent/CN104351612A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526445A (zh) * | 2011-11-07 | 2012-07-04 | 宁波海逸生物科技有限公司 | 一种增强免疫力、缓解体力疲劳、抗肿瘤功能的保健药物配方 |
| CN102907558A (zh) * | 2012-11-16 | 2013-02-06 | 山东省海洋水产研究所 | 一种海参多肽的加工方法 |
| CN102987203A (zh) * | 2012-12-05 | 2013-03-27 | 无锡市天赐康生物科技有限公司 | 一种提高免疫力、降血脂的保健食品及其制备方法 |
Non-Patent Citations (2)
| Title |
|---|
| 刘健敏等: "海参酶法水解的工艺研究", 《中国食品工业》 * |
| 胡长利等: "酵母β-葡聚糖在功能食品中的应用", 《中国乳业》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106213494A (zh) * | 2016-07-26 | 2016-12-14 | 柳州定店科技有限公司 | 一种虚弱体质调理的滋补药膳 |
| CN106690121A (zh) * | 2016-11-14 | 2017-05-24 | 威海力元海洋生物科技有限公司 | 一种海参沙棘虫草硒制剂及其制备工艺 |
| CN106723075A (zh) * | 2016-11-14 | 2017-05-31 | 威海力元海洋生物科技有限公司 | 一种双参沙棘g蛋白肉苁蓉锌硒制剂及其制备方法 |
| CN106723068A (zh) * | 2016-11-14 | 2017-05-31 | 威海力元海洋生物科技有限公司 | 一种海参番茄红素硒抗辐射胶囊配方及其制备工艺 |
| CN112790306A (zh) * | 2019-11-14 | 2021-05-14 | 舒培健康科学有限公司 | 一种用于补充气血的复合型小分子肽营养饮品及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015529670A (ja) | 免疫を調節する漢方薬組成物及びその製造方法 | |
| CN103750339B (zh) | 雪莲培养物保健食品及其用途 | |
| CN105595224A (zh) | 一种海参盐藻葡聚糖硒制剂及制备工艺 | |
| CN102153668B (zh) | 一种抗癌的黄绿蜜环菌多糖及提取工艺 | |
| CN104351612A (zh) | 一种海参灵芝葡聚糖硒制剂及其制备方法 | |
| CN104366480A (zh) | 一种减肥降脂营养代餐粉及其制备方法 | |
| CN105533710A (zh) | 一种海参壳寡糖硒制剂及制备工艺 | |
| KR100854698B1 (ko) | 홍삼 식이섬유 추출방법 및 상기 방법에 의하여 추출된홍삼 식이섬유 | |
| CN102349608A (zh) | 一种清咽润喉的保健品组合物及其制备方法 | |
| CN101380346A (zh) | 一种***的中药组合物及其制作方法 | |
| CN105664140A (zh) | 一种糖肽组合物及其制备方法和用途 | |
| CN105851185A (zh) | 一种具有抗疲劳功效的饼干及其制备方法 | |
| KR101272093B1 (ko) | 린테우스 상황버섯이 함유된 식용 달팽이 사료 및 그 사료를 이용한 식용 달팽이 사육방법 | |
| CN104256607A (zh) | 一种海参雪莲养生制品 | |
| CN101433329B (zh) | 一种用于保健功能的营养组合物 | |
| CN105999096A (zh) | 一种用于增强免疫力的组合物与应用 | |
| CN104799289A (zh) | 具有抗肿瘤提高免疫功能的复合营养食品及其生产方法 | |
| Ishihara et al. | Inhibition of decrease in natural killer cell activity in repeatedly restraint-stressed mice by a biological response modifier derived from cultured mycelia of the basidiomycete Tricholoma matsutake | |
| CN107549692A (zh) | 一种用于化疗患者术后恢复的海洋多肽特膳食品 | |
| CN106668077A (zh) | 海洋生物活性组合物及药用制剂 | |
| CN103933146A (zh) | 一种可调节人体免疫力的花粉制品 | |
| CN103710264B (zh) | 一种灵芝孢子的破壁辅助添加剂 | |
| CN100531791C (zh) | 抗肿瘤、抗癌药物 | |
| CN107307423A (zh) | 具有调节增强机体免疫功能的产品及制备方法 | |
| CN111329968A (zh) | 植物硒姬松茸灰树花片及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150218 |